| Elizabeth Marie Waltz, RPH | |
|
3201 S Iowa St, Lawrence, KS 66046-5205 | |
| (785) 832-0312 | |
| (785) 312-3452 |
| Full Name | Elizabeth Marie Waltz |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 3201 S Iowa St, Lawrence, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720701980 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-11107 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Marie Waltz, RPH 3201 S Iowa St, Lawrence, KS 66046-5205 Ph: () - | Elizabeth Marie Waltz, RPH 3201 S Iowa St, Lawrence, KS 66046-5205 Ph: (785) 832-0312 |
News Archive
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void.
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled "Methods for Treatment with Bucindolol Based on Genetic Targeting." The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued.
› Verified 7 days ago
Jakob Ready, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3421 W 6th St, Lawrence, KS 66049 Phone: 785-841-9000 | |
Carrie Lynn Williams, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2336 Ridge Ct, Ste C, Lawrence, KS 66046 Phone: 785-841-1950 Fax: 785-841-1051 | |
William J Anderson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1410 Kasold Dr, Ste A16, Lawrence, KS 66049 Phone: 785-843-8555 Fax: 785-843-0645 | |
Nikita Gandhi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2300 Iowa St, Lawrence, KS 66046 Phone: 785-832-1112 | |
Dr. Michelle Wessling, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 325 Maine St, Lawrence, KS 66044 Phone: 785-505-5127 | |
Bridget Ellen Gillespie, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 400 W 23rd Street, Lawrence, KS 66046 Phone: 785-832-8388 | |
Lauren Dick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1016 Lakecrest Rd, Lawrence, KS 66049 Phone: 785-218-9287 |